Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beyond Air, Inc. (NASDAQ: XAIR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to official information about this commercial-stage medical device and biopharmaceutical issuer. Beyond Air develops nitric oxide (NO) generators and delivery systems, including the LungFit platform, and pursues NO-based therapeutics in respiratory, neurological, and oncology indications. Its filings provide detailed context on these activities.
Core documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically describe the LungFit PH system, its FDA approval and CE Mark for neonatal hypoxic respiratory failure associated with pulmonary hypertension, the broader LungFit pipeline for severe lung infections, and affiliated programs like Beyond Cancer’s ultra-high concentration NO for solid tumors and NeuroNOS’s small-molecule nNOS inhibitors. Risk factors, R&D narratives, and segment information in these reports help readers understand the company’s NO-focused strategy and development stage.
Current reports on Form 8-K capture material events, including financing agreements such as promissory notes and equity purchase arrangements, warrant inducement transactions, reverse stock split implementation, leadership changes, and transactions involving subsidiaries like NeuroNOS. Registration statements, including Forms S-1 or S-3, outline the terms of securities offerings, equity lines of credit, and resale arrangements for investors like Streeterville Capital.
On this page, Stock Titan supplements raw filings data with AI-powered summaries that highlight key terms, financial obligations, and business implications from lengthy documents. Users can quickly identify items related to capital structure changes, Orphan Drug Designations, or regulatory milestones without reading every page. Real-time updates from EDGAR, combined with structured access to Forms 4 and other ownership reports, allow close monitoring of insider and institutional activity in XAIR. This makes the filings page a practical starting point for due diligence on Beyond Air’s regulatory, financial, and clinical disclosure record.
Beyond Air, Inc. has filed an S-3 shelf registration to allow existing investors to resell common stock and shares issuable from previously issued warrants. The filing covers 524,990 outstanding common shares, plus additional shares issuable from pre-funded warrants and common warrants.
The pre-funded warrants are exercisable at $0.0001 per share, and the common warrants are exercisable at $1.147 per share through January 16, 2031. Beyond Air will not receive proceeds from stockholder resales, but would receive cash if holders exercise these warrants. Shares outstanding were 10,529,344 as of January 22, 2026, and would be 17,865,990 if all warrant shares in this filing are issued.
Beyond Air, Inc. entered into a private placement with an institutional investor, agreeing to sell 524,990 common shares at $1.272 per share, pre-funded warrants to purchase up to 3,405,828 shares at $1.2719 per warrant, and common warrants to purchase up to 3,930,818 shares, for aggregate gross proceeds of $5,000,000. The pre-funded warrants have a nominal exercise price of $0.0001 per share and the common warrants have an exercise price of $1.147 per share and expire on January 16, 2031. The company agreed to register the resale of the shares and warrant shares by filing a registration statement by February 4, 2026, with effectiveness targeted within 60 to 90 days after January 14, 2026, and may owe liquidated damages if these deadlines are missed. Beyond Air will pay Rodman & Renshaw LLC a cash fee of 7% of gross proceeds and reimburse up to $50,000 of expenses and is subject to specified restrictions on additional equity issuances and variable rate transactions for defined periods.
Beyond Air, Inc. reported that XTL Biopharmaceuticals Ltd. has signed a binding letter of intent to acquire Beyond Air’s 85% ownership interest in NeuroNOS Ltd., a biotechnology company developing disease‑modifying therapeutics for Autism Spectrum Disorder and neuro‑oncology. Under the proposed terms, Beyond Air would receive 19.9% of XTL’s issued share capital, $1 million in cash, and milestone-based contingent payments of up to $31.5 million.
The companies are working to finalize definitive agreements for the transaction, which are expected to be filed in a future current report or in Beyond Air’s Annual Report on Form 10‑K. The disclosure emphasizes that these statements are forward‑looking and may differ from actual results.
Beyond Air, Inc. granted its Chief Financial Officer, Daniel J. Moorhead, a new stock option award. On January 5, 2026, he received an inducement grant of options to buy 70,000 shares of common stock at an exercise price of $0.79 per share, matching the closing price on January 2, 2026. The options expire on January 4, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 5, 2026, and the remaining 75% vest in three equal annual installments after that, as long as he remains employed. Any portion that is unexercisable when his employment ends will not become exercisable later. After this grant, he beneficially owns 70,000 stock options directly.
Beyond Air, Inc. is registering up to 1,600,000 shares of common stock for resale by Streeterville Capital, LLC. These shares may be issued to Streeterville under a $20 million Equity Purchase Agreement and, in some cases, as share issuances used to offset amounts outstanding under a $12,050,000 secured promissory note. Beyond Air will not receive proceeds from Streeterville’s resale of the registered shares, but may receive cash when it sells stock to Streeterville under the purchase agreement.
As of December 8, 2025, Beyond Air had 8,009,488 shares outstanding and a 4.99% beneficial ownership cap limits Streeterville’s holdings after each put. The company plans to use any cash raised from sales to Streeterville for general corporate purposes, including working capital, commercial operations, repayment of the note, and pre-clinical and clinical activities.
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on its LungFit® nitric oxide platform, including the LungFit® PH system, which has FDA approval and a European CE mark for specific respiratory and cardiac indications.
Beyond Air, Inc. appointed Denton "Duke" Dewrell as its principal financial officer and principal accounting officer on December 8, 2025.
Dewrell, age 39, has been the company’s Global Controller since April 2025, after serving as U.S. Controller from August 2024 and as Head of Finance and Controller of Beyond Cancer Ltd., a majority owned subsidiary, since August 2023.
He previously held senior finance roles at Updater Inc. and spent more than ten years in public accounting at Ernst & Young LLP. In his new role, he will continue to receive base compensation of $260,000 per year and participate in Beyond Air’s and Beyond Cancer’s equity incentive plans.
Beyond Air, Inc. (XAIR) reported an insider equity change for a director on Form 4. On November 4, 2025, the Board approved an option repricing effective that same day, reducing the exercise price of multiple stock option grants to $1.95 per share, which matches the closing price of Beyond Air’s common stock on November 3, 2025.
The filing shows that previously granted stock options with higher exercise prices, including options priced at $10.80 and $5.892 per share, were adjusted to the new $1.95 level. All other terms of the options, such as the number of underlying shares and expiration dates, remain unchanged.
The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan. They continue to vest according to the original vesting schedules set out in the award agreements, contingent on the reporting person’s continued service with Beyond Air on the applicable vesting dates.
Beyond Air, Inc. (XAIR) filed a Form 4 reporting that its Chief Operating Officer had existing stock options repriced. On November 4, 2025, the Board of Directors approved an option repricing, effective the same day, reducing the exercise price of several option grants to $1.95 per share, which was the closing price of Beyond Air’s common stock on November 3, 2025. All other terms of the options, including the number of shares and expiration details, remain unchanged.
The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan. They become exercisable based on the vesting schedule in the original award agreements, which continue to require the reporting person’s ongoing service with the company on each vesting date.
Beyond Air, Inc. has filed a Form S-1 to register the resale of up to 1,600,000 shares of common stock that may be issued to Streeterville Capital, LLC under an Equity Purchase Agreement. These shares, called Put Shares, will be issued over time at prices tied to the market price of XAIR stock, and Streeterville will act as an underwriter in reselling them.
The company may sell common stock to Streeterville for cash or, after certain offset events, by cancelling amounts outstanding under a $12,050,000 secured promissory note. Beyond Air may receive up to $20,000,000 in gross proceeds from sales of shares to Streeterville, but it will receive no proceeds from Streeterville’s resale of the registered shares. As of November 20, 2025, Beyond Air had 8,009,488 shares of common stock outstanding. The equity line is subject to a 4.99% beneficial ownership cap and Nasdaq’s 19.99% share issuance limitation.
Beyond Air (XAIR) reported Q2 FY2026 results. Revenue was $1.8 million, up from $0.8 million a year ago, but cost of revenues of $2.1 million produced a gross loss of $0.3 million. Operating expenses were $7.4 million, leading to a loss from operations of $7.7 million and a net loss of $8.3 million (basic and diluted loss per share $1.25).
Cash, cash equivalents, marketable securities and restricted cash totaled $10.9 million as of September 30, 2025. The company raised $8.1 million via its ATM program and received $2.9 million from warrant exercises during the six months. Long‑term debt, net, was $10.1 million, and management disclosed that recent results and projected cash outflows raise “substantial doubt” about the ability to meet obligations without additional financing.
The LungFit PH leasing business recognized $1.4 million in revenue in the quarter, and minimum future lease payments contracted total $11.1 million through 2029. Shares outstanding were 8,009,488 as of November 7, 2025; this is a baseline figure, not the amount being offered.